SLX-4090
As of the edition of 20 October 2026, SLX-4090 is a small molecule: stopped in 2020; acts on MTTP and P4HB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 5, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 4 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Response Pharmaceuticals | Lead sponsor of trials | 2007 to now |